152 related articles for article (PubMed ID: 31506879)
1. Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries.
Vogler S; Dedet G; Pedersen HB
Appl Health Econ Health Policy; 2019 Dec; 17(6):803-816. PubMed ID: 31506879
[TBL] [Abstract][Full Text] [Related]
2. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan.
Vogler S; Schneider P; Dedet G; Bak Pedersen H
Int J Equity Health; 2019 Jun; 18(1):89. PubMed ID: 31196109
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
4. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
5. The impact of prescription drug co-payments for publicly insured families.
Mohan G; Nolan A
Eur J Health Econ; 2020 Mar; 21(2):261-274. PubMed ID: 31705332
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.
Moye-Holz D; Vogler S
Appl Health Econ Health Policy; 2022 Jan; 20(1):67-77. PubMed ID: 34228312
[TBL] [Abstract][Full Text] [Related]
7. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
8. Reasons why insured consumers co-pay for medicines at retail pharmacies in Pretoria, South Africa.
Mpanza NM; Bradley H; Laing R
Afr J Prim Health Care Fam Med; 2019 Mar; 11(1):e1-e6. PubMed ID: 31038333
[TBL] [Abstract][Full Text] [Related]
9. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.
Ewen M; Zweekhorst M; Regeer B; Laing R
PLoS One; 2017; 12(2):e0171284. PubMed ID: 28170413
[TBL] [Abstract][Full Text] [Related]
10. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
11. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
[TBL] [Abstract][Full Text] [Related]
12. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
13. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
McRae I; van Gool K; Hall J; Yen L
Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
[TBL] [Abstract][Full Text] [Related]
14. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S;
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949
[TBL] [Abstract][Full Text] [Related]
15. Impact of the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales.
Alam MF; Cohen D; Dunstan F; Hughes D; Routledge P
Health Econ; 2018 Jan; 27(1):236-243. PubMed ID: 28685890
[TBL] [Abstract][Full Text] [Related]
16. Chronic conditions, financial burden and pharmaceutical pricing: insights from Australian consumers.
Whitty JA; Sav A; Kelly F; King MA; McMillan SS; Kendall E; Wheeler AJ
Aust Health Rev; 2014 Nov; 38(5):589-95. PubMed ID: 25099307
[TBL] [Abstract][Full Text] [Related]
17. The cost of prescription medicines to patients.
Noyce PR; Huttin C; Atella V; Brenner G; Haaijer-Ruskamp FM; Hedvall M; Mechtler R
Health Policy; 2000 Jun; 52(2):129-45. PubMed ID: 10794841
[TBL] [Abstract][Full Text] [Related]
18. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
